Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VVOS Vivos Therapeutics

Post-Mkt 02-03 17:29:51 EST

1.52

-0.10

-6.17%

盘后1.47

-0.05-3.29%

17:00 EST

High1.63	Low1.46	Vol174.76K
Open1.62	D1 Closing1.62	Amplitude10.49%
Mkt Cap17.36M	Tradable Cap14.21M	Total Shares11.42M
T/O267.13K	T/O Rate1.87%	Tradable Shares9.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VVOS","market":"US","secType":"STK","nameCN":"Vivos Therapeutics","latestPrice":1.52,"timestamp":1770152400000,"preClose":1.62,"halted":0,"volume":174759,"hourTrading":{"tag":"盘后","latestPrice":1.47,"preClose":1.52,"latestTime":"17:00 EST","volume":2486,"amount":3695.7701352,"timestamp":1770156001635,"change":-0.05,"changeRate":-0.032895,"amplitude":0.032895},"delay":0,"changeRate":-0.06172839506172845,"floatShares":9349500,"shares":11420100,"eps":-1.90536,"marketStatus":"Post-Mkt","change":-0.1,"latestTime":"02-03 17:29:51 EST","open":1.62,"high":1.63,"low":1.46,"amount":267125.3703963,"amplitude":0.104938,"askPrice":1.56,"askSize":1,"bidPrice":1.39,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-1.90536,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770166800000},"marketStatusCode":4,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":1.62,"preHourTrading":{"tag":"盘前","latestPrice":1.5279,"preClose":1.62,"latestTime":"08:59 EST","volume":2540,"amount":4039.709726,"timestamp":1770127194340,"change":-0.0921,"changeRate":-0.056852,"amplitude":0.087716},"postHourTrading":{"tag":"盘后","latestPrice":1.47,"preClose":1.52,"latestTime":"17:00 EST","volume":2486,"amount":3695.7701352,"timestamp":1770156001635,"change":-0.05,"changeRate":-0.032895,"amplitude":0.032895},"volumeRatio":1.599355,"impliedVol":2.594,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/VVOS","defaultTab":"news","newsList":[{"id":"2605142774","title":"Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2605142774","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605142774?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:31","pubTimestamp":1768948260,"startTime":"0","endTime":"0","summary":"LITTLETON, Colo., Jan.  20, 2026  (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep rel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/20/3222344/0/en/Vivos-Therapeutics-Announces-Closing-of-Exercise-of-Warrants-for-4-64-Million-Gross-Proceeds.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4196","CARE","VVOS"],"gpt_icon":0},{"id":"2605410301","title":"Vivos Therapeutics Completes Warrant Inducement Financing Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2605410301","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605410301?lang=en_us&edition=fundamental","pubTime":"2026-01-21 05:36","pubTimestamp":1768944989,"startTime":"0","endTime":"0","summary":"An announcement from Vivos Therapeutics ( ($VVOS) ) is now available. On January 15, 2026, Vivos Therapeutics entered into a warrant inducement agr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-completes-warrant-inducement-financing-transaction?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-completes-warrant-inducement-financing-transaction?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2605014910","title":"Vivos Therapeutics Raises $4.6 Million Through Warrant Exercise at Reduced Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2605014910","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605014910?lang=en_us&edition=fundamental","pubTime":"2026-01-21 05:07","pubTimestamp":1768943220,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics Inc. announced that it has entered into a warrant inducement agreement with an institutional investor, resulting in the exercise for cash of previously issued warrants to purchase shares of its common stock. The warrants, originally exercisable at prices of $3.83 and $5.05 per share, have been repriced to $2.34 per share pursuant to the inducement agreement. The exercise of these warrants is expected to generate approximately $4.6 million in gross proceeds for the company. The shares of common stock underlying the exercised warrants have been registered for resale with the SEC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via ED","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL52zRYx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2604091152","title":"Vivos Therapeutics Secures Convertible Bridge Financing Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2604091152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604091152?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:34","pubTimestamp":1768599251,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics ( ($VVOS) ) has shared an announcement. On January 15, 2026, Vivos Therapeutics, Inc. entered into an unsecured, non‑interest‑be...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-secures-convertible-bridge-financing-facility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-secures-convertible-bridge-financing-facility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2604196429","title":"Vivos Therapeutics Secures $5.5 Million in Unregistered Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2604196429","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604196429?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:06","pubTimestamp":1768597612,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics Inc. has entered into an unsecured convertible promissory note with V-Co Investors 3 LLC, an affiliate of New Seneca Partners Inc., for a maximum principal amount of up to $5.5 million. The funding is intended to support a proposed equity financing of the same amount, which the company expects to close by February 16, 2026. The note and any securities issued upon its conversion have not been registered under the Securities Act or state securities laws, and were offered in a private placement exempt from registration under Section 4 of the Securities Act. If the equity financing occurs before the specified date, the note will automatically convert into equity instruments issued in the financing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL1L3pgH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2603095995","title":"Vivos Therapeutics Raises $4.64 Million Through Warrant Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2603095995","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603095995?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:00","pubTimestamp":1768568426,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics Inc. announced the immediate exercise of certain outstanding warrants to purchase up to 1,982,356 shares of common stock at a reduced exercise price of $2.34 per share, generating approximately $4.64 million in gross proceeds. In connection with this, the company will issue new unregistered warrants in a private placement to purchase up to 3,964,712 shares of common stock at an exercise price of $2.09 per share. The new warrants will be immediately exercisable, with half expiring in five years and the other half in twenty-four months. Net proceeds will be used for working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL3P9Ktv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","BK4112","VVOS","BK4585","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014021.USD","SG9999014013.SGD","NDAQ","BK4196","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","SG9999014039.USD"],"gpt_icon":0},{"id":"2603823996","title":"Press Release: Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2603823996","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603823996?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:00","pubTimestamp":1768568400,"startTime":"0","endTime":"0","summary":"LITTLETON, Colo., Jan. 16, 2026  -- Vivos Therapeutics, Inc.  , a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea , today announced that it has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023, and February 20, 2024, at exercise prices ranging from $3.83 to $5.05 per share, at a reduced exercise price of $2.34 per share. The shares of common stock issuable upon exercise of the warrants are registered for resale pursuant to effective registration statement on Form S-3 . The gross proceeds to the company from the exercise of the warrants are expected to be approximately $4.64 million, prior to deducting placement agent fees and offering expenses.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARE","BK4211","BK4196","VVOS"],"gpt_icon":0},{"id":"2602375818","title":"Alliance Global Partners Sticks to Its Hold Rating for Vivos Therapeutics (VVOS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2602375818","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602375818?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:35","pubTimestamp":1767962138,"startTime":"0","endTime":"0","summary":"Alliance Global Partners analyst maintained a Hold rating on Vivos Therapeutics today and set a price target of $2.50. The word on The Street in ge...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-sticks-to-its-hold-rating-for-vivos-therapeutics-vvos-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-sticks-to-its-hold-rating-for-vivos-therapeutics-vvos-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS"],"gpt_icon":0},{"id":"2591298790","title":"Vivos Therapeutics Opens New Sleep Center in Auburn Hills, Michigan","url":"https://stock-news.laohu8.com/highlight/detail?id=2591298790","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591298790?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:45","pubTimestamp":1765892730,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics Inc., a leader in medical devices and healthcare services for sleep-related breathing disorders, has announced the grand opening of a new sleep testing and treatment center near Detroit in Auburn Hills, Michigan. This expansion is part of Vivos' national growth strategy, leveraging contractual alliances with local sleep clinics such as MISleep Solutions, LLC. The new center will offer Vivos' FDA-cleared diagnostic and therapeutic products for obstructive sleep apnea , aiming to bring innovative treatment options to a broader patient base while providing additional revenue streams for both Vivos and its affiliated providers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLb7LVW7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4112","LU2095319765.USD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","LU0314104364.USD","SG9999014039.USD","LU2210150020.SGD","IE00BKPKM429.USD","VVOS","NDAQ","BK4196","IE00BGHQF748.EUR","LU2210149790.SGD","BK4588","BK4585"],"gpt_icon":0},{"id":"2591627600","title":"Vivos Therapeutics Executives Join Water Tower Research Online Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2591627600","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591627600?lang=en_us&edition=fundamental","pubTime":"2025-12-16 06:30","pubTimestamp":1765837810,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics Inc. will participate in an online fireside chat with Water Tower Research on December 16, 2025, at 11:00 am ET. CEO Kirk Huntsman and CFO Brad Amman will discuss the company's strategic business model pivot, operational execution, market opportunity, competitive environment, and growth and financial strategies. The event is listen-only, and a replay will be available for 30 days in the Investor Relations section of the Vivos website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL2RJxtM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU0314104364.USD","BK4196","BK4585","IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","VVOS","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014039.USD","SG9999014005.SGD","LU2210149790.SGD","SG9999014021.USD"],"gpt_icon":0},{"id":"2589485048","title":"Vivos Therapeutics Secures $2.1 Million Unsecured Loan from Avondale Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2589485048","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589485048?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:13","pubTimestamp":1764972814,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics, Inc. has entered into a new unsecured debt financing arrangement with Avondale Capital, LLC, an affiliate of Streeterville Capital, LLC. Under the terms of the Note Purchase Agreement dated December 5, 2025, Vivos issued a promissory note with an original principal amount of $2,093,340, which includes an original issue discount and transaction costs. The company received approximately $1.5 million in gross proceeds from the note, which is not convertible into common stock and does not bear interest unless an event of default occurs. Weekly payments of $69,778 will begin on December 12, 2025, and the company may prepay the note without penalty, with an additional principal reduction offered for repayment by January 4, 2026. The note is guaranteed by Vivos's wholly-owned subsidiary, Airway Integrated Management Company, LLC. Proceeds from the financing will be used for working capital and general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDLxWPQx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","WNWG","BK4196","VVOS"],"gpt_icon":0},{"id":"2588436200","title":"Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2588436200","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588436200?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:56","pubTimestamp":1764762960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VVOS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 06:56 ET (11:56 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS"],"gpt_icon":0},{"id":"2585866122","title":"Vivos Therapeutics Reports Strong Q3 Growth Amid Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2585866122","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585866122?lang=en_us&edition=fundamental","pubTime":"2025-11-22 08:05","pubTimestamp":1763769951,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics, Inc. (($VVOS)) has held its Q3 earnings call. Read on for the main highlights of the call. Vivos Therapeutics, Inc. recently he...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-reports-strong-q3-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-reports-strong-q3-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2584011959","title":"Vivos Therapeutics Reports Revenue Growth Amid Strategic Shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2584011959","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584011959?lang=en_us&edition=fundamental","pubTime":"2025-11-20 11:56","pubTimestamp":1763611010,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics, Inc. ( ($VVOS) ) has released its Q3 earnings. Here is a breakdown of the information Vivos Therapeutics, Inc. presented to its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-reports-revenue-growth-amid-strategic-shift?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vivos-therapeutics-reports-revenue-growth-amid-strategic-shift?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS"],"gpt_icon":0},{"id":"2584762699","title":"Vivos Therapeutics Reports 78% Sequential Revenue Growth in Third Quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584762699","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584762699?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:45","pubTimestamp":1763588749,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics Inc. reported significant revenue growth for the third quarter of 2025, with a 78% sequential quarter-over-quarter increase and a 76% rise compared to the same period in the previous year. The company attributed the growth to its strategic shift from relying on a dental industry distribution channel to acquiring and affiliating with medical sleep practices and testing centers, highlighted by the June 2025 acquisition of The Sleep Center of Nevada. Further details and financial results for the three and nine months ended September 30, 2025, are available in the company's Quarterly Report on Form 10-Q filed with the SEC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original conte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL404MmW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2584768479","title":"Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2584768479","media":"Reuters","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584768479?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:30","pubTimestamp":1763587841,"startTime":"0","endTime":"0","summary":"Vivos Therapeutics Q3 revenue rises, helped by SCN acquisitionOverviewVivos Q3 2025 revenue rises 76% yr/yr, driven by SCN acquisitionCompany's gross margin declines to 58% from 60% due to pricing dis","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL1N3WV16C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","VVOS"],"gpt_icon":0},{"id":"2584761089","title":"Vivos Therapeutics reports Q3 EPS (49c), consensus (51c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584761089","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584761089?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:30","pubTimestamp":1763587818,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $6.78M, consensus $4.71M. Kirk Huntsman, Vivos’ chairman and CEO, stated, “We are very pleased to announce that our third quarte...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-reports-q3-eps-49c-consensus-51c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vivos-therapeutics-reports-q3-eps-49c-consensus-51c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VVOS"],"gpt_icon":0},{"id":"2584975273","title":"BRIEF-Vivos Therapeutics Q3 Net Income USD -5.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584975273","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584975273?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:20","pubTimestamp":1763587246,"startTime":"0","endTime":"0","summary":"BRIEF-Vivos Therapeutics Q3 Net Income USD -5.4 Million\n\n\nNov 19 (Reuters) - Vivos Therapeutics Q3 operating income USD -4.734 million.\n\nQ3 gross profit USD 3.937 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nPLX7430DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2584975758","title":"Vivos Therapeutics Inc - Qtrly Net Loss per Share Basic and Diluted $0.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2584975758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584975758?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:20","pubTimestamp":1763587201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nPLX7430DA:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VVOS","BK4196"],"gpt_icon":0},{"id":"2584975228","title":"Vivos Therapeutics Q3 Gross Profit USD 3.937 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584975228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584975228?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:20","pubTimestamp":1763587201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nPLX7430DA:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VVOS","BK4196"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vivos.com","stockEarnings":[{"period":"1week","weight":-0.0471},{"period":"1month","weight":-0.3597},{"period":"3month","weight":-0.3136},{"period":"6month","weight":-0.6501},{"period":"1year","weight":-0.5919},{"period":"ytd","weight":-0.202}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.099},{"period":"1year","weight":0.1555},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.205284},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.046239},{"month":3,"riseRate":0,"avgChangeRate":-0.220324},{"month":4,"riseRate":0.4,"avgChangeRate":-0.155798},{"month":5,"riseRate":0.4,"avgChangeRate":-0.052997},{"month":6,"riseRate":0.6,"avgChangeRate":0.052001},{"month":7,"riseRate":0.4,"avgChangeRate":-0.104292},{"month":8,"riseRate":0.6,"avgChangeRate":0.170604},{"month":9,"riseRate":0,"avgChangeRate":-0.252021},{"month":10,"riseRate":0.2,"avgChangeRate":-0.105489},{"month":11,"riseRate":0.4,"avgChangeRate":1.251693},{"month":12,"riseRate":0.2,"avgChangeRate":-0.12992}],"exchange":"NASDAQ","name":"Vivos Therapeutics","nameEN":"Vivos Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vivos Therapeutics(VVOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vivos Therapeutics,VVOS,Vivos Therapeutics股票,Vivos Therapeutics股票老虎,Vivos Therapeutics股票老虎国际,Vivos Therapeutics行情,Vivos Therapeutics股票行情,Vivos Therapeutics股价,Vivos Therapeutics股市,Vivos Therapeutics股票价格,Vivos Therapeutics股票交易,Vivos Therapeutics股票购买,Vivos Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vivos Therapeutics(VVOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vivos Therapeutics(VVOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}